Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecules that target lysine-specific demethylase 1 (LSD1), an essential enzyme in the production of blood cells in the bone marrow. Bomedemstat, is an orally available LSD1 inhibitor discovered by Imago being tested in clinical studies as a potentially disease-modifying therapy for myeloproliferative neoplasms (MPNs), a family of chronic cancers of the bone marrow, including essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV).